Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.43 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.42 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.42 |
| ▸ | TUBB | P07437 | 4/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.42 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.42 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.42 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13402248 | 0.79 | PTGS2 (0.37) | CYP3A4MAPTALOX5 | |
| SCHEMBL5587062 | 0.74 | GABRA1 (0.37) | CYP3A4MAPTALOX5 | |
| SCHEMBL3860745 | 0.74 | CYP3A4 (0.42) | CYP3A4MAPTALOX5TUBB1TUBB4A | |
| SCHEMBL9768502 | 0.72 | CYP3A4 (0.58) | CYP3A4MAPTALOX5TUBB1TUBB4A | |
| SCHEMBL18029847 | 0.71 | ALOX5 (0.75) | ALOX5 | |
| SCHEMBL5572443 | 0.71 | PTGS2 (0.59) | CYP3A4MAPTTUBB1TUBB4ATUBB | |
| SCHEMBL5587869 | 0.70 | MAPT (0.56) | CYP3A4MAPTALOX5TUBB1TUBB4A | |
| SCHEMBL21715984 | 0.69 | CYP3A4 (0.54) | CYP3A4MAPTALOX5TUBB1TUBB4A | |
| SCHEMBL18029894 | 0.68 | ALOX5 (0.38) | CYP3A4MAPTALOX5TUBB1TUBB4A | |
| Pregomisin SCHEMBL29045386 | 0.68 | ALOX15 (0.62) | CYP3A4MAPTALOX5TUBB1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856083-A4 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | UNIV MICHIGAN (US) | 2009-05-27 | — | — | EP | disclosed |
| CN-101171241-A | Chromen-4-one inhibitors of anti-apoptotic BCL-2 family members and the uses thereof | UNIV MICHIGAN (US) | 2008-04-30 | — | — | CN | disclosed |
| EP-1856083-A2 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060247305-A1 | Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006099193-A2 | CHROMEN-4-ONE INHIBITORS OF ANTI-APOPTOTIC BCL-2 FAMILY MEMBERS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247305-A1 | Chromen-4-one inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof | BCL2, BAD, BAX | CYP3A4 2385/4885MAPT 3970/4885ALOX5 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.